Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 1/20 | 0.76 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.76 |
| ▸ | PTGFR | P43088 | 7/20 | 0.60 |
| ▸ | PTGER3 | P43115 | 5/20 | 0.60 |
| ▸ | MGLL | Q99685 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.49 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.48 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.45 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15655151 | 1.00 | ABCB11 (0.76) | ABCB11AKR1C3PTGFRPTGER3MGLL | |
| SCHEMBL13278021 | 1.00 | ABCB11 (0.76) | ABCB11AKR1C3PTGFRPTGER3MGLL | |
| SCHEMBL13468604 | 1.00 | ABCB11 (0.76) | ABCB11AKR1C3PTGFRPTGER3MGLL | |
| SCHEMBL13960683 | 0.92 | ABCB11 (0.78) | ABCB11AKR1C3PTGFRPTGER3MGLL | |
| SCHEMBL4875027 | 0.91 | ABCB11 (0.80) | ABCB11AKR1C3PTGFRPTGER3MGLL | |
| SCHEMBL13960682 | 0.91 | ABCB11 (0.80) | ABCB11AKR1C3PTGFRPTGER3MGLL | |
| SCHEMBL13960684 | 0.90 | ABCB11 (0.79) | ABCB11AKR1C3PTGFRPTGER3MGLL | |
| SCHEMBL19200057 | 0.89 | ABCB11 (0.83) | ABCB11AKR1C3PTGFRPTGER3MGLL | |
| SCHEMBL12964800 | 0.89 | ABCB11 (0.77) | ABCB11AKR1C3PTGFRPTGER3MGLL | |
| SCHEMBL94570 | 0.89 | ABCB11 (0.77) | ABCB11AKR1C3PTGFRPTGER3MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140120058-A1 | POLYMER CONJUGATED PROSTAGLANDIN ANALOGUES | POLYACTIVA PTY LTD | 2014-05-01 | — | — | US | disclosed |
| EP-2696899-A1 | POLYMER CONJUGATED PROSTAGLANDIN ANALOGUES | Polyactiva Pty Ltd (AU) | 2014-02-19 | — | — | EP | disclosed |
| WO-2012139164-A1 | POLYMER CONJUGATED PROSTAGLANDIN ANALOGUES | POLYACTIVA PTY LTD (AU) | 2012-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140120058-A1 | POLYMER CONJUGATED PROSTAGLANDIN ANALOGUES | PTGIS, PTGS2, PTGES | ABCB11 45/4885AKR1C3 607/4885PTGFR 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.